A single-blind, randomised, phase II UK multi-centre study to determine reactogenicity and immunogenicity of booster vaccination against ancestral and novel variants of SARS-CoV-2 (COV-BOOST)

£314.73M GBP

Funder	National Institute for Health and Care Research
Recipient Organization	University Hospital Southampton Nhs Foundation Trust
Country	United Kingdom
Start Date	Apr 18, 2021
End Date	Mar 31, 2025
Duration	1,443 days
Number of Grantees	2
Roles	Principal Investigator; Award Holder
Data Source	NIHR Open Data-Funded Portfolio
Grant ID	`NIHR203292`

Grant Description

The 2 vaccines which have been delivered at scale in the UK so far have been the mRNA vaccine BNT162b2 (Pfizer) and the chimpanzee adenovirus vector vaccine ChAdOx1-nCov19 (Oxford/AstraZeneca).

Studies are underway currently to examine the effect of heterologous prime-boost regimens using these differing vaccine technologies (the COM-COV trial, IRAS Project ID: 291055 EudraCT Number: 2020-005085-33).

The COV-BOOST trial aims to establish the safety and efficacy of annual boosting vaccination with different authorised vaccine candidates for participants who have received homologous prim-boosting with either BNT162b2 or ChAdOx1-nCov19 early in the UK NHS deployment campaign.

In addition, this study will examine the safety and efficacy of boosting using vaccines designed specifically to target novel variants of the SARS-CoV-2 virus when these vaccines become available.